No

Anticonvulsant, Oxazolidinedione

Control absence (petit mal) seizures refractory to other drugs

D

Hypersensitivity to trimethadione

May cause severe blood dyscrasias; use with caution in patients with renal and hepatic impairment, SLE, myasthenia gravis, or intermittent porphyria; do not abruptly discontinue medication

Central nervous system: Drowsiness, hiccups

Dermatologic: Alopecia, exfoliative dermatitis, rash

Endocrine & metabolic: Porphyria

Gastrointestinal: Anorexia, vomiting, stomach upset, abdominal pain, weight loss

Hematologic: Aplastic anemia, agranulocytosis, thrombocytopenia,

Hepatic: Hepatitis, jaundice

Neuromuscular & skeletal: Myasthenia gravis-like syndrome

Ocular: Diplopia, photophobia, hemeralopia, nystagmus, scotomata

Renal: Nephrosis, proteinuria

Miscellaneous: Lupus

Use caution with other centrally-acting agents

An oxazolidinedione with anticonvulsant sedative properties; elevates the cortical and basal seizure thresholds, and reduces the synaptic response to low frequency impulses

Oral:

Adults: Initial: 900 mg/day in 3-4 equally divided doses, increase by 300 mg/day at weekly intervals until therapeutic results or toxic symptoms appear

Dosing interval in renal impairment:

Cl_cr 10-50 mL/minute: Administer every 8-12 hours

Cl_cr <10 mL/minute: Administer every 12-24 hours

No information available to require special precautions

No effects or complications reported

Blood test monitoring must be performed periodically, notify physician of persistent or severe fatigue, sore throat, fever, rash, unusual bleeding or bruising; may take with food, may cause drowsiness, impair judgment and coordination, and blurred vision; visual disturbances are normally controlled by reduction of dose

Caution patient that even minor skin rash and signs of infection or bleeding must be reported to the physician

Capsule: 300 mg

Tablet, chewable: 150 mg